Profusa (PFSA) and The Competition Financial Review

Profusa (NASDAQ:PFSA) is one of 27 publicly-traded companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it compare to its rivals? We will compare Profusa to related businesses based on the strength of its valuation, analyst recommendations, institutional ownership, earnings, profitability, dividends and risk.

Profitability

This table compares Profusa and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-880.32%
Profusa Competitors	-569.68%	-123.14%	-53.62%

Analyst Ratings

This is a summary of recent ratings and target prices for Profusa and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1	0	0	0	1.00
Profusa Competitors	80	82	163	7	2.29

As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 54.99%. Given Profusa’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Profusa has less favorable growth aspects than its rivals.

Institutional & Insider Ownership

9.8% of Profusa shares are owned by institutional investors. Comparatively, 19.3% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by institutional investors. 11.4% of Profusa shares are owned by insiders. Comparatively, 19.9% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Profusa and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Profusa	N/A	-$8.71 million	-0.01
Profusa Competitors	$61.19 million	-$27.52 million	1.49

Profusa’s rivals have higher revenue, but lower earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Profusa has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500. Comparatively, Profusa’s rivals have a beta of 1.80, indicating that their average stock price is 80% more volatile than the S&P 500.

Summary

Profusa rivals beat Profusa on 10 of the 13 factors compared.

Profusa Company Profile

NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.